1:5 Stock Split: Pharma Stock Gains 32.94% After Approval, Trades Ex-Split Today

Small cap Pharmaceutical sector stock Gujarat Themis Biosyn traded 52-week high today as its shares are set to ex-split today in the proportion of 1:5. Gujarat Themis Biosyn stock gained 4.51% intraday to 219.00 per share on BSE. It is worth noting that its board of directors approved stock split on September 9 and since then Gujarat Themis Biosyn stock witnessed a rally of nearly 33%. Gujarat Themis Biosyn shares offered shareholders return of 2979% in last 5 years and 338% return in last 3-years. Check details here:

Gujarat Themis Shares Trade Ex-Split Today: As per the exchange filing of Gujarat Themis Biosyn issued on September 20, 2023 "With reference to the captioned subject and in terms of Regulation 42 of the SEBI Listing Regulations, the Company has fixed Tuesday, 10th October, 2023 as the 'Record Date' for the purpose of determining the eligibility of Shareholders for the purpose of sub-division/split of every one fully paid-up Equity share having face value Rs. 5/- (Rupees Five only) each in the authorised share capital of the Company, into 5 (five) fully paid-up Equity shares having face value of Rs. 1/- (Rupee One only) each, as approved by the shareholders at the 42nd Annual General Meeting of the Company held on 9th September, 2023."

Gujarat Themis Shares Performance, Return: Current market price of Gujarat Themis Biosyn share on BSE is Rs 219.00 per share on BSE. Its 52-week high price is Rs 228.70 per share and 52-week low price is Rs 114.42 per share. The company has a market capitalisation of Rs 1,566.92 crore. Gujarat Themis Biosyn shares gained 33% in last 1-months, soared 58% in last 6-months, surged 56% in last 1-year time, rose 89% in last 2-years, and offered return of 338% in last 3-years.

Gujarat Themis Financial Outlook: The pharma company for the quarter ended June 30, 2023 announced net sales at Rs 49.59 crore, up 10.33% as compared to Rs Rs 44.94 crore announced in June 2022. The company's quarterly net profit declared at Rs 17.72 crore in June 2023, down 0.27% as against Rs 17.77 crore in June 2022. It announced its EBITDA at Rs 24.58 crore in June 2023, up 1.57% as against Rs 24.20 crore in June 2022.

Gujarat Themis About: It was incorporated in 1981 as a joint sector company with GIIC Ltd and Chemosyn (P) Ltd. The company started production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin, according to its official website.

Disclaimer

The stock just highlights the rally in shares and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.